Uterine carcinosarcoma: a rare and aggressive neoplasm
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20252169Keywords:
Postmenopause, Neoplasm, Uterine carcinosarcomaAbstract
Uterine carcinosarcoma (UCS) is a rare highly aggressive tumor accounting for 2-3% of all uterine malignancies. It’s characterized by postmenopausal bleeding and often presents with a palpable pelvic mass. The tumors usually contain both malignant epithelial carcinomatous and sarcomatous mesenchymal components. Herewith presenting a case report of a patient with postmenopausal bleeding with a 16 weeks size lump in the abdomen.
Metrics
References
Rojas C, Tian C, Powell MA, Chan JK, Bateman NW, Conrads TP, et al. Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival. Gynecol Oncol. 2020;157(1):67-77. DOI: https://doi.org/10.1016/j.ygyno.2020.01.017
Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet. 2003;83(1):79-118. DOI: https://doi.org/10.1016/S0020-7292(03)90116-0
Ferguson SE, Geisler JP, Geisler HE, Richard RB, Robert AS. Carcinosarcoma of the uterus: a clinicopathologic study of 61 cases. Am J Surg Pathol. 2007;31(10):1653-61. DOI: https://doi.org/10.1097/PAS.0b013e3181161ba3
Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol. 2010;22(1):21-9. DOI: https://doi.org/10.1097/GCO.0b013e328334d8a3
Black JD, English DP, Roque DM, Santin AD. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer. Womens Health. 2014;10(1):45-57. DOI: https://doi.org/10.2217/WHE.13.72
Hayes MP, Ellenson LH. Molecular alterations in uterine serous carcinoma. Gynecol Oncol. 2010;116(2):286-9. DOI: https://doi.org/10.1016/j.ygyno.2009.11.012
Gallup DG, Gable DS, Talledo OE, Otken LB Jr. A clinical-pathologic study of mixed mullerian tumors of the uterus over a 16-year period-the medical college of Georgia experience. Am J Obstet Gynecol. 1989;161:533-8. DOI: https://doi.org/10.1016/0002-9378(89)90352-9
Ali S, Wells M. Mixed mullerian tumors of the uterine corpus: A review. Int J Gynecol Cancer. 1993;3:1-11. DOI: https://doi.org/10.1046/j.1525-1438.1993.03010001.x
Villena-Heinsen C, Diesing D, Fischer D, Griesinger G, Maas N, Diedrich K, Friedrich M. Carcinosarcomas-a retrospective analysis of 21 patients. Anticancer Res. 2006;26:4817-23.
Barwick KW, LiVolsi VA. Malignant mixed Mullerian tumors of the uterus. A clinicopathologic assessment of 34 cases. Am J Surg Pathol. 1979;3:125-35. DOI: https://doi.org/10.1097/00000478-197904000-00003
Norris HJ, Roth E, Taylor HB. Mesenchymal tumors of the uterus. II. A clinical and pathologic study of 31 mixed mesodermal tumors. Obstet Gynecol. 1966;28:57-63.
Rauh-Hain JA, Shoni M, Schorge JO, Goodman A, Horowitz NS, del Carmen MG. Prognostic determinants in patients with uterine and ovarian carcinosarcoma. J Reprod Med. 2013;58:297-304.
Jin Z, Ogata S, Tamura G, Katayama Y, Fukase M, Yajima M, Motoyama T. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: A genetic study with special reference to histogenesis. Int J Gynecol Pathol. 2003;22:368-73. DOI: https://doi.org/10.1097/01.pgp.0000092134.88121.56
Li L, Huang W, Xue K, Feng L, Han Y, Wang R, et al. Clinical and imaging features of carcinosarcoma of the uterus and cervix Insights Imaging. 2021;12(1):142. DOI: https://doi.org/10.1186/s13244-021-01084-5
Kamishima Y, Takeuchi M, Kawai T, Kawaguchi T, Yamaguchi K, Takahashi N, et al. A predictive diagnostic model using multiparametric MRI for differentiating uterine carcinosarcoma from carcinoma of the uterine corpus. Jpn J Radiol. 2017;35(8):472-83. DOI: https://doi.org/10.1007/s11604-017-0655-6
Bharwani N, Newland A, Tunariu N, Babar S, Sahdev A, Rockall AG, et al. MRI appearances of uterine malignant mixed mullerian tumors. Am J Roentgenol. 2010;195(5):1268-75. DOI: https://doi.org/10.2214/AJR.10.4419
Li Y, Ren H, Wang J. Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study. BMC Cancer. 2019;19(1):697. DOI: https://doi.org/10.1186/s12885-019-5879-7
Shinde A, Li R, Amini A, Chen YJ, Cristea M, Dellinger T, et al. Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology. Gynecol Oncol. 2018;151(1):82-90. DOI: https://doi.org/10.1016/j.ygyno.2018.08.028
Cantrell LA, Havrilesky L, Moore DT, O'Malley D, Liotta M, Secord AA, et al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma Gynecol Oncol. 2012;127(1):22-6. DOI: https://doi.org/10.1016/j.ygyno.2012.06.020
Gonzalez Bosquet J, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, et al. The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol. 2010;116:419-23. DOI: https://doi.org/10.1016/j.ygyno.2009.10.053
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Caruso G, et al. Endometrial carcinosarcoma. Int J Gynecol Cancer. 2023;33:147-74. DOI: https://doi.org/10.1136/ijgc-2022-004073
Downloads
Published
How to Cite
Issue
Section
